RVMD
Revolution Medicines (NASDAQ: RVMD) jumped 12% in premarket trading Monday after new data showed...
Article Summary
HOLD- Revolution Medicines (NASDAQ: RVMD) jumped 12% in premarket trading Monday after new data showed daraxonrasib delayed worsening painful symptoms for more than nine months compared with chemotherapy, extending survival to 13.2 months in a late-stage study.
- The drug could be one of the more important early attempts to broadly target RAS, a protein tied to tumor growth and mutated in most pancreatic cancers, extending across patient groups with different genetic mutations, giving the drug broader clinical profile than narrow mutation-specific therapy.
- Johnson & Johnson (NYSE: JNJ) presented data that could possibly shift how some high-risk early-stage prostate cancers are treated, with Erleada plus hormone therapy and surgery reducing risk of tumors spreading to distant organs by 20% over five years compared with hormone-suppressing drugs and surgery alone, with about 60,000 US patients a year falling into the early-risk category.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | -100.0% | 25% | 0.0 ptsDeclining (-100.0%) - NOT a growth stock |
| EPS Growth Next 5Y ? | 27.9% | 25% | 80.0 ptsVery Good (27.9%) - Good outlook |
| Target Price Upside ? | 14.2% | 20% | 50.0 ptsMeets Minimum (14.2%) - Target: $185.52 vs Current: $162.41 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | 2.7% | 15% | 20.0 ptsBarely a Dip (2.7%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About RVMD
- Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
- The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
- Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C).
- Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.